Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

NCT06030843 is registered in ClinicalTrials.gov with Chulalongkorn University as lead sponsor.

NCT NCT06030843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06030843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Lead sponsor
Chulalongkorn University
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 1, 2025
Completion date
December 31, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

empagliflozin in cardiorenal syndrome type 1